Search | Clinical Trials Finder

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: PF-04217329, latanoprost vehicle, latanoprost; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: Cypress, California • Garden Grove, California • Gardena, California + 4 more

Conditions: Allergic Conjunctivitis
Interventions: RX-10045, Vehicle for RX-10045 arm; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Acquired Blepharoptosis
Interventions: RVL-1201, RVL-1201 Vehicle Placebo; Drug
Lead sponsor: RVL Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Artesia, California • Newport Beach, California • Rancho Cordova, California + 11 more

Conditions: Cystic Fibrosis
Interventions: Lucinactant first, Placebo first; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 14 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions: SHP639 (n=60), Placebo Comparator (n=24); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Atopic Keratoconjunctivitis
Interventions: DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Jacksonville, Florida • Miami, Florida • Morrow, Georgia + 5 more

Conditions: Oily Skin
Interventions: Acetyl Hexapeptide-8, Placebo vehicle; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Dry Eye Syndromes
Interventions: Ecabet 2.83%, Ecabet 3.70%, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 3
States / cities: Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire

Conditions: Obesity, Morbid Obesity
Interventions: Placebo, RM-493; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Erythema
Interventions: MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Dry Eye Disease
Interventions: PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 13
States / cities: Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more

Conditions: Allergic Conjunctivitis
Interventions: Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Artesia, California • Mission Hills, California • Newport Beach, California + 9 more

Conditions: Dry Eye
Interventions: NGF, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye
Interventions: Oxervate, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more

Conditions: Urinary Catheter Blockage and Encrustation
Interventions: Auriclosene Irrigation Solution, 0.2%, Auriclosene Vehicle Solution; Drug
Lead sponsor: NovaBay Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 14 more

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more

Conditions: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.; Drug · Other · Device
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more

Conditions: Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions: Vehicle of TP-03; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Northridge, California • Shelby, North Carolina

Conditions: Onychomycosis
Interventions: terbinafine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 11
States / cities: Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more

Conditions: Nail Psoriasis
Interventions: P-3073 (calcipotriene 0.005%), Vehicle of P-3073; Drug
Lead sponsor: Polichem S.A.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more

Search by objective public record fields.

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Effects of RM-493 on Energy Expenditure in Obese Individuals

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s